Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic Resection, Chemotherapy, and Proton Radiation for Unresectable Sinonasal Tumors
NCT03274414Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2017
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin in Paranasal Sinus Cancer (NPSC), Nasal cavity tumors, Adenocarcinoma of the nasal cavity and 1 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors at 1 year. Started Sep 2017; status: completed.
02
Drugs
cisplatin
03
Conditions
Paranasal Sinus Cancer (NPSC)Nasal cavity tumorsAdenocarcinoma of the nasal cavitysinonasal undifferentiated carcinoma (SNUC)
Beyond the preview
Go deeper on NCT03274414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274414.